Polydex Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended October 31, 2021. For the third quarter, the company reported sales was USD 1.1 million compared to USD 1.23 million a year ago. Net loss was USD 0.068676 million compared to net income of USD 0.023607 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to basic earnings per share from continuing operations of USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to diluted earnings per share from continuing operations of USD 0.01 a year ago. For the nine months, sales was USD 3.28 million compared to USD 3.45 million a year ago. Net loss was USD 0.297118 million compared to net income of USD 0.146408 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to basic earnings per share from continuing operations of USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.09 compared to diluted earnings per share from continuing operations of USD 0.04 a year ago.